MUSK and myasthenia gravis: The proportion of patients with MuSK Ab+ gMG enrolled in the study (10.5% [n = 21]) was representative of the proportion of patients with this subtype of MG in the real world (5%–8% of patients).7 Further, the number of patients with MuSK Ab+ gMG is the largest to be enrolled in a randomised controlled phase III study.